<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278248</url>
  </required_header>
  <id_info>
    <org_study_id>201719906</org_study_id>
    <nct_id>NCT04278248</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above</brief_title>
  <official_title>A Randomized, Blinded, Parallel Controlled, Phase Ⅲ Clinical Trial to Evaluate Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal
      Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Actual">June 7, 2018</completion_date>
  <primary_completion_date type="Actual">June 7, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity study endpoint</measure>
    <time_frame>30 day after each vaccination</time_frame>
    <description>Percentage of participants with seroresponse to each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety study endpoint</measure>
    <time_frame>30 day after each vaccination</time_frame>
    <description>Occurrence of adverse events during a 30 day follow-up period after each vaccination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1940</enrollment>
  <condition>Pneumonia, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine(experimental vaccine), 0.5 ml/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine (positive control vaccine), 0.5 ml/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-Valent Pneumococcal Polysaccharide Vaccine</intervention_name>
    <description>1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.</description>
    <arm_group_label>Positive control group</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 years old and above healthy people.

          -  Subject or legal representative who consent and has signed written informed consent.

          -  Subject or legal representative who is able to comply with all study procedures.

          -  Subject who didn't vaccinate pneumococcal vaccines and did't immune with any live
             vaccine within 14 days and inactivated vaccine within 7 days before vaccination.

          -  Axillary temperature ≤37.0 ℃.

        Exclusion Criteria:

          -  History of allergy，eclampsia, epilepsy, encephalopathy and mental disease or family
             disease.

          -  Allergic history after vaccination.

          -  Known allergy to any component of the test vaccine（the test vaccine mainly contains 23
             types of pneumococcal polysaccharide and PBS buffer）

          -  Subjects who diagnosis of thrombocytopenia or other history of coagulopathy.

          -  Known immunological impairment or dysfunction.

          -  Subjects who have received whole blood, plasma, and immunoglobulin therapy within one
             month.

          -  Known severe congenital malformations, developmental disorders; clinically diagnosed
             serious chronic diseases: down's syndrome, diabetes, sickle cell anemia or
             neurological disorders, Guillain Barre syndrome.

          -  Known or suspected to suffer from: respiratory system disease，acute infection or
             chronic disease active period，severe cardiovascular disease, liver and kidney disease,
             malignant tumor, skin disease,children's mother has HIV infection and other serious
             and infectious diseases.

          -  In pregnancy or lactation or pregnant women.

          -  Subjects aged 18 years and above whose systolic blood pressure≥160mmHg and diastolic
             blood pressure≥100mmHg.

          -  Any contraindications that investigators consider related to vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Du Lin, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yizhou Center for Disease Control and Prevention</name>
      <address>
        <city>Yizhou</city>
        <state>Guangxi</state>
        <zip>530028</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

